title: Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
abstract: BACKGROUND
  Adenocarcinoma of the esophagus is frequently associated with Barrett's esophagus (BE). The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported.
  
  
  OBJECTIVE
  To determine the response of tumor-associated BE to chemoradiation therapy.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  A single National Cancer Institute Comprehensive Cancer Care Center experience.
  
  
  METHODS
  The study cohort consisted of 43 patients with stage I to IVA esophageal adenocarcinoma associated with BE who received either neoadjuvant or definitive chemoradiation therapy and underwent either esophagectomy or surveillance at our institution.
  
  
  METHODS
  The presence and extent of BE after chemoradiation therapy of esophageal adenocarcinoma associated with endoscopically documented pretreatment BE.
  
  
  RESULTS
  BE persisted after chemoradiation therapy in 93% (40/43) of cases (95% CI, 83%-99%). Twenty-seven patients received neoadjuvant chemoradiation therapy before esophagectomy. Persistent BE was detected in all 27 surgical specimens (100%). In 59% (16/27) of the cases, there was complete pathologic tumor response. Sixteen patients received definitive chemoradiation therapy. Persistent pretreatment BE was identified in 88% (14/16) by surveillance endoscopy (95% CI, 60%-98%). The mean length of BE before and after chemoradiation was 6.6 cm and 5.8 cm, respectively (P = .38).
  
  
  CONCLUSIONS
  Retrospective design, small sample size, and single-site data collection.
  
  
  CONCLUSIONS
  Chemoradiation therapy of esophageal adenocarcinoma does not eliminate tumor-associated BE, nor does it affect the length of the BE segment.
authors.affiliation: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
authors.forename: James S
authors.initials: JS
authors.lastname: Barthel
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Kucera
authors.forename: James L
authors.initials: JL
authors.lastname: Lin
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Hoffe
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Strosberg
authors.forename: Irfan
authors.initials: I
authors.lastname: Ahmed
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Dilling
authors.forename: Craig W
authors.initials: CW
authors.lastname: Stevens
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002471:Cell Transformation, Neoplastic; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000473:pathology*; D011336:Probability; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome